The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
John Hainsworth
Consulting or Advisory Role - Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst)
 
Ron Bose
Consulting or Advisory Role - Genentech
Research Funding - Puma Biotechnology (Inst)
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst); Novartis (Inst)
Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Novartis (Inst); Pfizer (Inst); Vincerx Pharma (Inst)
 
Claire Frances Friedman
Honoraria - Aptitude Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - Seagen
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech; Merck
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; IDbyDNA
Honoraria - AACR; Advanced Therapeutics; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; Meyer Consulting; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; Bicara Therapeutics; Gaido; Loxo; Merck; NeoMed; Pfizer; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - Roche
Research Funding - Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley
 
Charles Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Apogen Biotechnologies; Epic Sciences; GRAIL
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Illumina; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - Bicycle Therapeutics; Genentech/Roche; Medicxi; Sarah Cannon Research Institute
Research Funding - Archer; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ono Pharmaceutical; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Immune checkpoint intervention in cancer (PCT/EP2016/071471),; Method for determining whether an HLA allele is lost in a tumour (PCT/GB2018/052004); Method for identifying responders to cancer treatment (PCT/GB2018/)051912); Method for treating cancer (PCT/EP2016/059401).; Method for treating cancer based on identification of clonal neo-antigens (PCT/EP2016/059401); Method of detecting tumour recurrence (PCT/GB2017/053289); Method of identifying insertion/deletion mutation targets (PCT/GB2018/051892); Method of predicting survival rates for cancer patients (PCT/GB2020/050221); Method of treating cancer by targeting insertion/deletion mutations (PCT/GB2018/051893); Methods for lung cancer detection (PCT/US2017/028013)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst)
 
Yong Wang
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Jonathan Levy
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Katja Schulze
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Research Funding - Genentech
 
Richard Price
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Arisha Patel
Employment - Genentech/Roche
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination